PMS-Salbutamol Product Monograph

Recent Major Label Changes

Table of Contents

Certain sections or subsections that are not applicable at the time of the preparation of the most recent authorized product monograph are not listed.

Recent Major Label Changes .................................................................................................... 2

Table of Contents ..................................................................................................................... 2

Part 1: Healthcare Professional Information ............................................................................. 4

1. 1.

   Indications .......................................................................................................................... 4

   1.1. Pediatrics ..................................................................................................................... 4

   1.2. Geriatrics ..................................................................................................................... 4

2. 2. Contraindications ............................................................................................................... 4
3. 4.

   Dosage and Administration ................................................................................................ 4

   4.1. Dosing Considerations ................................................................................................. 4

   4.2. Recommended Dose and Dosage Adjustment ............................................................ 5

   4.4. Administration ............................................................................................................ 5

   4.5. Missed Dose ................................................................................................................ 6

4. 5. Overdose ............................................................................................................................ 6
5. 6. Dosage Forms, Strengths, Composition and Packaging ....................................................... 6
6. 7.

   Warnings and Precautions .................................................................................................. 7

   General ................................................................................................................................... 7

   Cardiovascular ......................................................................................................................... 7

   Endocrine and Metabolism ..................................................................................................... 8

   Immune .................................................................................................................................. 8

   Neurologic ............................................................................................................................... 8

   Respiratory .............................................................................................................................. 8

   7.1. Special Populations ................................................................................................... 10

   7.1.1. Pregnancy ................................................................................................................. 10

   7.1.2. Breast-feeding ........................................................................................................... 10

   7.1.3. Pediatrics ................................................................................................................... 11

   7.1.4. Geriatrics ................................................................................................................... 11

7. 8.

   Adverse Reactions ............................................................................................................ 11

   8.1. Adverse Reaction Overview ....................................................................................... 11

8. 9.

   Drug Interactions .............................................................................................................. 12

   9.4. Drug-Drug Interactions .............................................................................................. 12

   9.5. Drug-Food Interactions ............................................................................................. 14

   9.6. Drug-Herb Interactions .............................................................................................. 14

   9.7. Drug-Laboratory Test Interactions ............................................................................. 14

9. 10.

   Clinical Pharmacology ...................................................................................................... 14

   10.1. Mechanism of Action ................................................................................................ 14

   10.2. Pharmacodynamics ................................................................................................... 14

   10.3. Pharmacokinetics ...................................................................................................... 15

10. 11. Storage, Stability, and Disposal ......................................................................................... 15

Part 2: Scientific Information .................................................................................................. 17

1. 13. Pharmaceutical Information ............................................................................................. 17
2. 14.

   Clinical Trials ..................................................................................................................... 18

   14.1. Clinical Trials by Indication ......................................................................................... 18

3. 15. Microbiology .................................................................................................................... 19
4. 16. Non-Clinical Toxicology ..................................................................................................... 19

17 Supporting Product Monographs ...................................................................................... 22

Patient Medication Information ............................................................................................. 23

Part 1: Healthcare Professional Information

1. Indications

Adults and Children (5 years and older):

pms-SALBUTAMOL (salbutamol sulfate inhalation solution) is indicated for:

• the treatment of severe bronchospasm associated with exacerbations of chronic bronchitis and bronchial asthma.

1.1. Pediatrics

Pediatrics (< 5 years of age):

No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use in patients less than 5 years of age.

Pediatrics (5 years of age and older): Based on the available information to Health Canada, pms-SALBUTAMOL has been authorized for pediatric patients 5 to < 18 years of age.

1.2. Geriatrics

No dosage adjustment is required in geriatric patients. Caution should be observed for patients with concomitant cardiovascular disease that could be adversely affected by beta2-agonists.

2. Contraindications

• pms-SALBUTAMOL is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container and in patients with tachyarrhythmias. For a complete listing, see 6 Dosage Forms, Strengths, Composition and Packaging).
• pms-SALBUTAMOL is contraindicated as a tocolytic in patients at risk of premature labour or threatened abortion.

4. Dosage and Administration

4.1. Dosing Considerations

The dosage should be individualized, and the patient’s response should be monitored by the prescribing physician on an ongoing basis.

Increasing demand for pms-SALBUTAMOL in bronchial asthma is usually a sign of poorly controlled or worsening asthma and indicates that the patient should be reevaluated, the treatment plan should be reviewed and the regular asthma controller treatment should be optimized. If inhaled salbutamol treatment alone is not adequate to control asthma, concomitant anti-inflammatory therapy should be part of the treatment regimen.

If a previously effective dose fails to provide the usual relief, or the effects of a dose last for less than three hours, patients should seek prompt medical advice since this is usually a sign of worsening asthma.

As there may be adverse effects associated with excessive dosing, the dosage or frequency of administration should only be increased on medical advice. However, if a more severe attack has not been relieved by the usual dose, additional doses may be required. In these cases, patients should immediately consult their healthcare professional or the nearest hospital.

4.2. Recommended Dose and Dosage Adjustment

Adults and Adolescents (≥ 13 years of age): Patients requiring single doses of 2.5 mg or 5 mg of salbutamol may be administered the contents of a single pms-SALBUTAMOL unit dose (a 1 mg/mL [2.5 mg] or 2 mg/mL [5 mg] strength unit). Treatment may be repeated every 4 to 6 hours as needed to a maximum 4 times a day if necessary.

Pediatrics (5 - 12 years): Children requiring a single dose of 1.25 mg or 2.5 mg of salbutamol may be administered the contents of a single pms-SALBUTAMOL unit dose (a 0.5 mg/mL [1.25 mg] or 1 mg/mL [2.5 mg] strength unit). For more refractory cases, children may use a single pms-SALBUTAMOL 5 mg unit dose (a 2 mg/mL strength unit). Treatment may be repeated every 4 to 6 hours as needed to a maximum 4 times a day if necessary.

If a more severe attack has not been relieved by a treatment, further treatments may be required. In these cases, patients should be advised to immediately consult their healthcare professional or the nearest hospital.

4.4. Administration

To ensure administration of the proper dose of the drug, the patient should be instructed by a healthcare professional on the proper use of the nebulizer system.

For inhalation use only. The solution must not be injected or swallowed.

pms-SALBUTAMOL is to be used only under the direction of a physician employing a nebulizer. pms-SALBUTAMOL can only be taken with a nebulizer.

Nebulization

pms-SALBUTAMOL can be used by “wet” nebulization. When used in a nebulizer, delivery may be by a mouthpiece, a face mask, T piece or via an endotracheal tube. The nebulizer should be connected to a compressed air or oxygen pump. Gas flow should be in the range of 6 to 10 L/minute. A single treatment lasts approximately 10 minutes.

Storage and Use

pms-SALBUTAMOL in Polyneb® is to be used with a nebulizer, under the direction of a healthcare professional. pms-SALBUTAMOL in Polyneb® is intended to be used undiluted. However, if prolonged delivery time is desirable (more than 10 minutes) dilution using sterile normal saline as a diluent may be required.

Cleansing and maintenance of the nebulizer must be carefully exercised by strict adherence to the manufacturer's instructions.

4.5. Missed Dose

If a single dose is missed, instruct the patient to take the next dose at the time when it is due or if they become wheezy.

5. Overdose

Symptoms and Signs

The most common signs and symptoms of overdose with salbutamol are transient beta agonist pharmacologically mediated events (see 7 Warnings and Precautions; and 8.1 Adverse Reaction Overview). Overdosage may cause tachycardia, cardiac arrhythmia, hypokalemia, hypertension and, in extreme cases, sudden death. Serum potassium levels should be monitored.

Lactic acidosis has been reported in association with high therapeutic doses as well as overdoses of short-acting beta-agonist therapy, therefore monitoring for elevated serum lactate and consequent metabolic acidosis (particularly if there is persistence or worsening of tachypnea despite resolution of other signs of bronchospasm such as wheezing) may be indicated in the setting of overdose.

Treatment

Consideration should be given to discontinuation of treatment and appropriate symptomatic therapy. To antagonise the effect of salbutamol, the judicious use of a cardioselective beta-adrenergic blocking agent (e.g. metoprolol, atenolol) may be considered, bearing in mind the danger of inducing an asthmatic attack. During continuous administration of pms-SALBUTAMOL, any signs of overdosage can usually be counteracted by withdrawal of the drug.

For the most recent information in the management of a suspected drug overdose, contact your regional poison control centre or Health Canada’s toll-free number, 1-844 POISON-X (1-844-764-7669).

6. Dosage Forms, Strengths, Composition and Packaging

Table 1: Dosage Forms, Strengths, Composition and Packaging

Description

pms-SALBUTAMOL in Polyneb® (0.5 mg/mL, 1 mg/mL, 2 mg/mL) contains salbutamol sulfate equivalent to 0.5 mg, 1 mg or 2 mg of salbutamol base (equivalent to 0.5 mg/mL, 1 mg/mL or 2 mg/mL) in 2.5 mL. It is a sterile, prediluted with Sodium Chloride Solution 0.9%. It also contains Sulfuric Acid (to adjust pH) and Water for Injection. Available in packages of 10 and 20 Polyneb® nebules. Each Polyneb® contains 2.5 mL of solution.

7. Warnings and Precautions

General

Patients should always carry their salbutamol aerosol or dry powder to use immediately if an episode of asthma is experienced. If therapy does not produce a significant improvement or if the patient’s condition worsens, medical advice must be sought to determine a new plan of treatment. In the case of acute or rapidly worsening dyspnea, a healthcare professional should be consulted immediately.

The application of these inhalation systems in children depends on the ability of the individual child to learn the proper use of the devices. During inhalation, children should be assisted or supervised by an adult who knows the proper use of the devices.

pms-SALBUTAMOL must only be used by inhalation, to be breathed in through the mouth, and must not be injected or swallowed.

A small number of cases of acute angle closure glaucoma have been reported in patients treated with a combination of nebulized salbutamol and ipratropium bromide. A combination of nebulized pms-SALBUTAMOL with nebulized anticholinergics should therefore be used cautiously. Patients should receive adequate instruction in correct administration and be warned not to let the solution or mist enter the eye.

Cardiovascular

Controlled clinical studies and other clinical experience have shown that inhaled salbutamol, like other beta-adrenergic agonist drugs, can produce a significant cardiovascular effect in some patients, as measured by heart rate, blood pressure, symptoms, and/or ECG changes.

Care should be taken with patients suffering from cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias and hypertension. Special care and supervision are required in patients with idiopathic hypertrophic subvalvular aortic stenosis, in whom an increase in the pressure gradient between the left ventricle and the aorta may occur, causing increased strain on the left ventricle.

Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma. The exact cause of death is unknown, but cardiac arrest following an unexpected development of a severe acute asthmatic crisis and subsequent hypoxia is suspected.

Endocrine and Metabolism

• Metabolic Effects

  In common with other beta-adrenergic agents, salbutamol can induce reversible metabolic changes such as potentially serious hypokalemia, particularly following nebulized or especially infused administration. Particular caution is advised in acute severe asthma since hypokalemia may be potentiated by concomitant treatment with xanthine derivatives, steroids and diuretics and by hypoxia. Hypokalemia will increase the susceptibility of digitalis-treated patients to cardiac arrhythmias. It is recommended that serum potassium levels be monitored in such situations.

  Care should be taken with patients with diabetes mellitus. Salbutamol can induce reversible hyperglycemia during nebulized administration or especially during infusions of the drug. The diabetic patient may be unable to compensate for this and the development of ketoacidosis has been reported. Concurrent administration of corticosteroids can exaggerate this effect.

  Lactic acidosis has been reported very rarely in association with high therapeutic doses of intravenous and nebulized short-acting beta-agonist therapy, mainly in patients being treated for an acute asthma exacerbation (see 8.1 Adverse Reaction Overview). Increase in lactate levels may lead to dyspnea and compensatory hyperventilation, which could be misinterpreted as a sign of asthma treatment failure and lead to inappropriate intensification of short-acting beta-agonist treatment. It is therefore recommended that patients are monitored for the development of elevated serum lactate and consequent metabolic acidosis in this setting.

  Care should be taken with patients with hyperthyroidism.

Immune

• Hypersensitivity

  Immediate hypersensitivity reactions may occur after administration of salbutamol sulfate, as demonstrated by rare cases of urticaria, angioedema, rash, bronchospasm, hypotension, anaphylaxis, and oropharyngeal edema.

  Care should be taken with patients who are unusually responsive to sympathomimetic amines.

Neurologic

Care should be taken with patients with convulsive disorders.

Respiratory

As with other inhaled medications, paradoxical bronchospasm may occur characterized by an immediate increase in wheezing after dosing. This should be treated immediately with an alternative presentation or a different fast-acting inhaled bronchodilator to relieve acute asthmatic symptoms. pms-SALBUTAMOL should be discontinued immediately, the patient assessed and if necessary, alternative therapy instituted (see 8.1 Adverse Reaction Overview). The cause of either the refractory state or death is unknown. However, it is suspected in the fatal episodes that cardiac arrest occurred following the unexpected development of a severe acute asthmatic crisis and subsequent hypoxia.

Several cases have been reported in which intermittent positive pressure ventilation in acute asthma attacks was related to lethal episodes of hypoxia and pneumothorax. This method of drug administration may be ineffective in patients with severe obstruction and greatly increased airway resistance, and it may induce severe hypercapnia and hypoxia. During intermittent ventilation therapy, the monitoring of arterial blood gases is highly desirable. It is advisable that in the event of either hypoxia and pneumothorax or paradoxical bronchospasm the use of the preparation should be discontinued immediately and alternate therapy instituted, since in the reported cases the patients did not respond to other forms of therapy until the drug was withdrawn.

The management of asthma should normally follow a stepwise program and patient response should be monitored clinically and by lung function tests.

• Monitoring Control of Asthma

  Failure to respond for at least three hours to a previously effective dose of pms-SALBUTAMOL indicates a deterioration of the condition and a healthcare professional should be contacted promptly. Patients should be warned not to exceed the recommended dose as there may be adverse effects associated with excessive dosing.

  The increasing use of fast acting, short duration inhaled beta₂-adrenergic agonists, such as salbutamol, to control symptoms indicates deterioration of asthma control and the patient’s therapy plan should be reassessed by a healthcare professional.

  Patients who are taking pms-SALBUTAMOL more than twice a week on an “as needed” basis, not counting prophylactic use prior to a known trigger should be re-evaluated (i.e., daytime symptoms, nighttime awakening, and activity limitation due to asthma) for proper treatment adjustment as these patients are at risk for overuse of pms-SALBUTAMOL. A reassessment of the patient's therapy plan may be required.

  In worsening asthma, it is inadequate to increase beta₂-agonist use only, especially over an extended period of time. In the case of acute or rapidly worsening dyspnea, a healthcare professional should be consulted immediately.

  Overuse of short-acting beta-agonists may mask the progression of the underlying disease and contribute to deteriorating asthma control, leading to an increased risk of severe asthma exacerbations and mortality.

  Sudden or progressive deterioration in asthma control is potentially life-threatening; the treatment plan must be re-evaluated, and consideration be given to corticosteroid therapy (see 4.1 Dosing Considerations).

  Patients who are prescribed regular asthma anti-inflammatory therapy (e.g., inhaled corticosteroids) should be advised to continue taking their anti-inflammatory medication even when symptoms improve, and they no longer require pms-SALBUTAMOL.

• Deterioration of Asthma

  Asthma may deteriorate over time. If the patient needs to use pms-SALBUTAMOL more often than usual, this may be a sign of worsening asthma. This requires re-evaluation of the patient and treatment plan and consideration of adjusting the asthma maintenance therapy. If inhaled salbutamol treatment alone is not adequate to control asthma, concomitant anti-inflammatory therapy should be part of the treatment regimen. It is essential that the physician instructs the patient on the need for further evaluation if the patient’s asthma becomes worse (see 4.1 Dosing Considerations).

7.1. Special Populations

7.1.1. Pregnancy

Salbutamol has been in widespread use for many years in humans without apparent ill consequence. However, there are no adequate and well-controlled studies in pregnant women and there is little published evidence of its safety in the early stages of human pregnancy. Administration of any drug to pregnant women should only be considered if the anticipated benefits to the expectant woman are greater than any possible risks to the fetus (see 16 Non-Clinical Toxicology, Teratogenicity Studies).

During worldwide marketing experience, rare cases of various congenital anomalies, including cleft palate and limb defects have been reported in the offspring of patients being treated with salbutamol. Some of the mothers were taking multiple medications during their pregnancies. Because no consistent pattern of defects can be discerned, and baseline rate for congenital anomalies is 2-3%, a relationship with salbutamol use cannot be established.

Labour and Delivery:

Although there have been no reports concerning the use of inhaled salbutamol during labour and delivery, intravenously administered salbutamol given at high doses may inhibit uterine contractions. While this effect is extremely unlikely as a consequence of using inhaled formulations, it should be kept in mind. Oral salbutamol has been shown to delay preterm labour in some reports but there are no well-controlled studies which demonstrate that it will stop preterm labour or prevent labour at term. When given to pregnant patients for relief of bronchospasm, cautious use of pms-SALBUTAMOL is required to avoid interference with uterine contractility.

7.1.2. Breast-feeding

Since salbutamol is probably excreted in breast milk and because of its observed tumorigenicity in animal studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the benefit of the drug to the mother. It is not known whether salbutamol in breast milk has a harmful effect on the neonate.

7.1.3. Pediatrics

Pediatrics (5 – 12 years of age): pms-SALBUTAMOL should be used under the supervision of an adult who understands the proper use of the nebulizer, and only as presented by the healthcare professional.

Rarely, in children, hyperactivity occurs and occasionally, sleep disturbances, hallucination or atypical psychosis have been reported.

Pediatrics (< 5 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use in patients less than 5 years of age.

7.1.4. Geriatrics

As with other beta₂-agonists, special caution should be observed when using pms-SALBUTAMOL in elderly patients who have concomitant cardiovascular disease that could be adversely affected by this class of drug.

8. Adverse Reactions

8.1. Adverse Reaction Overview

Adverse events are listed below; frequencies are defined as: very common (≥ 1/10), common (≥ 1/100 and < 1/10), uncommon (≥ 1/1000 and < 1/100), rare (≥ 1/10,000 and < 1/1000) and very rare (< 1/10,000) including isolated reports. Very common and common events were generally determined from clinical trial data. Rare, very rare and unknown events were generally determined from spontaneous data.

As with other bronchodilator inhalation therapy, the potential for paradoxical bronchospasm should be kept in mind. If it occurs, the preparation should be discontinued immediately and alternative therapy instituted.

Potentially serious hypokalemia may result from beta₂-agonist therapy, primarily from parenteral and nebulized routes of administration (see 7 Warnings and Precautions, Endocrine and Metabolism, Metabolic Effects).

Peripheral vasodilation and a compensatory small increase in heart rate may occur in some patients. Cardiac arrhythmias (including atrial fibrillation, supraventricular tachycardia and extrasystoles) have been reported, usually in susceptible patients.

The most frequent adverse reactions associated with salbutamol inhalation aerosol, dry powder or respirator solution formulation are nervousness and tremor. In some patients inhaled salbutamol may cause a fine tremor of skeletal muscle, particularly in the hands. This effect is common to all beta₂-adrenergic agonists. Adaptation occurs during the first few days of dosing and the tremor usually disappears as treatment continues.

Headache, palpitations, transient muscle cramps, insomnia, nausea, weakness and dizziness have been reported as untoward effects following salbutamol administration.

Rarely reported adverse effects include drowsiness, flushing, restlessness, irritability, chest discomfort, difficulty in micturition, hypertension, angina, vomiting, vertigo, central nervous system stimulation, hyperactivity in children, unusual taste and drying or irritation of the oropharynx.

Immediate hypersensitivity reactions including angioedema, urticaria, bronchospasm, hypotension, rash, oropharyngeal oedema, anaphylaxis and collapse have been reported very rarely.

Rarely, in children, hyperactivity occurs and occasionally, sleep disturbances, hallucination or atypical psychosis have been reported.

Lactic acidosis has been reported very rarely in patients receiving intravenous and nebulized salbutamol therapy for the treatment of acute asthma exacerbation.

9. Drug Interactions

9.4. Drug-Drug Interactions

The drugs listed in this table are based on either drug interaction case reports or studies, or potential interactions due to the expected magnitude and seriousness of the interaction (i.e., those identified as contraindicated).

Table 2: Established or Potential Drug-Drug Interactions

Legend: CS=Class Statement

9.5. Drug-Food Interactions

Interactions of salbutamol with food have not been established.

9.6. Drug-Herb Interactions

Interactions of salbutamol with herbal products have not been established.

9.7. Drug-Laboratory Test Interactions

Interactions of salbutamol with laboratory tests have not been established.

10. Clinical Pharmacology

10.1. Mechanism of Action

Salbutamol produces bronchodilation through stimulation of beta₂-adrenergic receptors in bronchial smooth muscle, thereby causing relaxation of bronchial muscle fibres. This action is manifested by an improvement in pulmonary function as demonstrated by spirometric measurements. Although beta₂-receptors are the predominant adrenergic receptors in bronchial smooth muscle and beta₁-receptors are the predominant receptors in the heart, there are also beta₂-receptors in the human heart comprising 10% to 50% of the total beta-adrenergic receptors. The precise function of these receptors has not been established, but they raise the possibility that even highly selective beta₂-agonists may have cardiac effects. At therapeutic doses, salbutamol has little action on the beta₁-adrenergic receptors in cardiac muscle.

A measurable decrease in airway resistance is typically observed within 5 to 15 minutes after inhalation of salbutamol. The maximum improvement in pulmonary function usually occurs 60 to 90 minutes after salbutamol treatment, and significant bronchodilator activity has been observed to persist for 3 to 6 hours.

10.2. Pharmacodynamics

Prolonged use of salbutamol in most patients caused no significant changes in ECG pattern, blood sugar, liver and kidney functions and hematological values.

The hemodynamic effects of intravenous salbutamol were studied in patients with mitral valve disease. At the dose of 1 mcg/kg, salbutamol reduced mean aortic pressure by 7 mmHg, increased the cardiac output by 0.6 L/minute and reduced systemic vascular resistance by 7 units. It caused no change in left ventricular ejection time. At the dose of 2 mcg/kg, salbutamol increased the mean oxygen uptake by 21 mL/minute, narrowing the mean arteriovenous oxygen difference by 10 mL/minute. Salbutamol has no effect on the pulmonary ventilation/perfusion ratio, therefore, unlike isoprenaline, it does not increase hypoxia during acute asthmatic attacks.

10.3. Pharmacokinetics

After inhalation of recommended doses of salbutamol, plasma drug levels are very low. When 100 mcg of tritiated salbutamol aerosol was administered to two normal volunteers, plasma levels of drug-radioactivity were insignificant at 10, 20 and 30 minutes following inhalation. The plasma concentration of salbutamol may be even less as the amount of plasma drug-radioactivity does not differentiate salbutamol from its principal metabolite, a sulfate ester. In a separate study, plasma salbutamol levels ranged from less than 0.5 ng/mL to 1.6 ng/mL in ten asthmatic children one hour after inhalation of 200 mcg of salbutamol.

Five asthmatic patients were given tritium-labelled salbutamol from the nebulizer of an intermittent positive pressure ventilator. In all patients, there was a rapid initial rise in plasma concentration of total radioactivity. In four of the five patients, there was a further rise in plasma concentration to a peak at 2 to 4 hours. All patients showed an improvement in forced expiratory volume in one second (FEV₁) with peak improvement at 30 minutes to 2 hours. An average of 12.5% of the initial dose was recovered in the urine. Of the radioactivity recovered, 88% was recovered in the first 24 hours. The metabolite in the urine was the same as that in the plasma. During the first 2 hours, the ratio of free salbutamol to metabolite average 2:1, whereas by 8 hours, the ratio was 9:11, and thereafter this reversed ratio was maintained.

Approximately 10% of an inhaled salbutamol dose is deposited in the lungs. Eighty-five percent of the remaining salbutamol administered from a metered-dose inhaler is swallowed, however, since the dose is low (100 to 200 mcg), the absolute amount swallowed is too small to be of clinical significance. Salbutamol is only weakly bound to plasma proteins. Results of animal studies indicate that following systemic administration, salbutamol does not cross the blood-brain barrier but does cross the placenta using an in vitro perfused isolated human placenta model. It has been found that between 2% and 3% of salbutamol was transferred from the maternal side to the fetal side of the placenta.

Salbutamol is metabolized in the liver. The principal metabolite in humans is salbutamol-o-sulfate, which has negligible pharmacologic activity. Salbutamol may also be metabolized by oxidative deamination and/or conjugation with glucuronide.

Salbutamol is longer acting than isoprenaline in most patients by any route of administration because it is not a substrate for the cellular uptake processes for catecholamines nor for catechol-O-methyl transferase. Salbutamol and its metabolites are excreted in the urine (>80%) and the feces (5% to 10%). Plasma levels are insignificant after administration of aerosolized salbutamol; the plasma half-life ranges from 3.8 to 7.1 hours.

1. 11. Storage, Stability, and Disposal

Keep out of reach and sight of children.

Store between 15^oC and 25^oC. Protect from light.

In the home, the Polyneb® (0.5 mg/mL, 1 mg/mL and 2 mg/mL) preparation, which is pre-diluted and ready to use, is the most convenient preparation. Any unused solution in the nebulizer should be discarded. Discard any unused Polyneb® in opened foil packs after 3 months.

Part 2: Scientific Information

13. Pharmaceutical Information

Drug Substance

Proper name: salbutamol sulfate

Chemical name: 1, 3-Benzenedimethanol, α1-[(1, 1-dimethylethyl) amino] methyl]-4-hydroxy-sulfate

Molecular formula and molecular mass: (C₁₃H₂₁NO₃)₂.H₂SO₄ and 576.71 g/mol

Structural formula:

OH OH OH N CH₃ CH₃ CH₃ H 2 ¤ H₂SO₄

Physicochemical properties:

Description: White to almost white powder. It is odourless or almost odourless.

Solubility: Soluble in 4 parts of water; slightly soluble in ethanol, in chloroform and in ether.

pH value: 5.8 (1% solution)

pKa values: 9.3 and 10.3

Distribution Coefficient: The distribution coefficient of salbutamol between two phases of octanol and water, as determined by HPLC, is log D=-0.5 at pH 7.42 at room temperature.

Melting Point: Approximately 155°C, with decomposition

14. Clinical Trials

14.1. Clinical Trials by Indication

Severe bronchospasm associated with exacerbations of chronic bronchitis and bronchial asthma

In controlled clinical trials, the onset of improvement in pulmonary function was within 15 minutes, as determined by both maximum mid-expiratory flow rate (MMEF) and FEV₁. MMEF measurements also showed that near maximum improvement in pulmonary function generally occurs within 60 to 90 minutes following two inhalations of salbutamol and that clinically significant improvement generally continues for three to four hours in most patients. In clinical trials some patients with asthma showed a therapeutic response (defined as maintaining FEV₁ values 15% or more above baseline) that was still apparent at six hours. Continued effectiveness of salbutamol was demonstrated over a 13-week period in these same trials.

In clinical studies, two inhalations of salbutamol taken approximately 15 minutes before exercise prevented exercise-induced bronchospasm, as demonstrated by the maintenance of FEV₁ within 80% of baseline values in the majority of patients. One of these studies also evaluated the duration of the prophylactic effect to repeated exercise challenges which was evident at four hours in the majority of patients and at six hours in approximately one third of the patients.

The ability of salbutamol to produce bronchodilation in humans has been demonstrated in many spirometric and plethysmographic studies. Following a challenge with acetylcholine aerosol, in a study examining the effects of salbutamol in airway resistance following challenge testing in 12 patients, the mean airway resistance increased 250%. After salbutamol aerosol (200 mcg), the mean airway resistance decreased to 78% of the initial value. Challenges with grass pollen or house dust aerosols in five and eight patients, respectively, increased activity resistance 265% and 255%, respectively. Administration of salbutamol decreased airway resistance to initial levels.

A double-blind, placebo-controlled comparison of the bronchodilator effects of salbutamol, inhaled either as a dry powder or as a conventional aerosol, was carried out in 20 adult patients with chronic bronchial asthma. All treatments were significantly better than placebo. There was no significant difference between responses to any of the three dry powder doses (100 mcg, 200 mcg, 300 mcg) but the average response to 200 mcg aerosol was significantly greater than that to 200 mcg dry powder.

Salbutamol dry powder (400 mcg) and conventional aerosol (200 mcg) were administered to 10 adult asthmatics. There was no statistically significant difference between the improvement in FEV₁ obtained 10 minutes after administration of either the dry powder or the aerosol formulation.

Salbutamol was administered as a dry powder (50 mcg, 100 mcg, 200 mcg, 400 mcg) and as an aerosol (200 mcg) to 10 adult asthmatics. The greatest responses were obtained with salbutamol 400 mcg administered as a dry powder. No effect on blood pressure or pulse rate was observed.

Daily improvement in peak expiratory flow rate (PEFR) in response to single doses of inhaled salbutamol (200 mcg dry powder and 100 mcg conventional aerosol) was measured in nine asthmatic children (aged 5-13 years) for six weeks. The order of administration of powder and aerosol was reversed at the end of three weeks. There was no statistically significant difference between the increase in PEFR 5 minutes after either 200 mcg dry powder or after 100 mcg aerosol. The total mean increases in PEFR 10 minutes after inhalation of powder and aerosol (weeks 1-3) and inhalation of aerosol and powder (weeks 4-6) were not significantly different.

In a double-blind, placebo-controlled study, salbutamol (200 mcg) completely prevented exercise-induced bronchospasm in three of five children, and greatly reduced the effects in the other two patients.

Administration of 10 mg salbutamol as a 0.5% solution through Intermittent Positive-Pressure Ventilation (IPPV) from a Bennett ventilator, given in a 3 minute period, resulted in a 40% increase of FEV1 with maximum effect in about 90 minutes. The average duration of effect was 3 hours. The heart rate had an average increase of 9 beats/minute, peaking after 25 minutes, and lasting for about 36 minutes. No ECG changes were observed.

Salbutamol solution 0.5% was self-administered at home via a portable nebulizer, without IPPV, by 28 adult patients with severe chronic asthma. The dose was 0.5 mL (2.5 mg salbutamol) in 4.5 mL normal saline, 2 to 4 times daily, and the duration of treatment period ranged from 0.9 to 2.7 years (mean 1.7 years). For each patient the treatment period was compared retrospectively with a control period of the same duration preceding nebulizer therapy. No statistically significant differences between treatment and control periods were found for pulmonary function tests performed before and after 5 puffs of a salbutamol pressurized aerosol, or for number of out-patient emergency department visits, hospitalizations, sick leaves, and days hospitalized. However, there were significant reductions during the treatment period in the duration of sick leaves and medical ward treatments, while half of the patients reported that it was easier to sleep and two-thirds said it was easier to exercise.

In 10 pediatric studies, a total of 189 patients up to 14 years of age were treated with salbutamol solution 0.5% administered via a portable nebulizer. In most cases, the dose was between 0.5 mL and 1 mL per treatment, diluted with normal saline, bringing the total volume to 2 mL. Children with asthma had very good results from the treatment, while children with bronchitis or bronchiolitis did not respond well. Salbutamol was very well tolerated in these studies. One author reported 2 cases of skeletal muscle tremor, but drew attention to the fact that both patients received concurrent oral bronchodilator. Otherwise, the only reported side effect was occasional mild tachycardia.

15. Microbiology

No microbiological information is required for this drug product.

16. Non-Clinical Toxicology

Animal Pharmacology

In vitro studies and in vivo pharmacologic studies have demonstrated that salbutamol has a preferential effect on beta₂-adrenergic receptors compared with isoprenaline. While it is recognized that beta₂-adrenergic receptors are the predominant receptors in bronchial smooth muscle, recent data indicate that there is a population of beta₂-receptors in the human heart existing in a concentration between 10% and 50%. The precise function of these, however, is not yet established.

The pharmacologic effects of beta-adrenergic agonist drugs, including salbutamol, are at least in part attributable to stimulation through beta-adrenergic receptors of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increased cAMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.

The muscle-relaxing effect of salbutamol was found to be more prolonged than when the effect was induced by isoprenaline. As suggested from the results of experiments in isolated animal tissues, salbutamol has been shown to produce a substantial bronchodilator effect in the intact animal. In the anaesthetized guinea pig, salbutamol completely prevents acetylcholine-induced bronchospasm at the dose of 100 mcg/kg intravenously.

Administration of salbutamol aerosol at a dose of 250 mcg/mL for one minute to guinea pigs prevented acetylcholine-induced bronchospasm without any chronotropic effect. A prolonged bronchodilator effect of salbutamol compared to isoprenaline (in terms of mean times to dyspnea following acetylcholine challenge) was observed following oral administration of salbutamol to conscious guinea pigs. The protective action of salbutamol in this case persisted for up to six hours.

In anaesthetized cats and dogs, salbutamol prevented the bronchospasm elicited by vagal stimulation without any significant effect on heart rate and blood pressure. Comparative tests of salbutamol and isoprenaline in isolated dog papillary muscle, guinea pig atrial muscle and human heart muscle have shown that the effect of salbutamol on beta₁-adrenergic receptors in the heart is minimal.

In a number of studies using guinea pig atria, it was found that on a weight-to-weight basis, salbutamol was from 2,000 to 2,500 times less active in terms of inotropic effect and 500 times less active in terms of chronotropic effect than isoprenaline. Compared to orciprenaline, salbutamol was about 40 times less active in terms of inotropic effect and four times less potent in terms of chronotropic effect. Salbutamol has been shown to be one-fifth as potent a vasodilator in skeletal muscle as isoprenaline, as measured by effects on hind limb blood flow in the anaesthetized dog. In the perfused rabbit ear, salbutamol was shown to possess only one-tenth the activity of isoprenaline in terms of vasodilating effect. In dogs, salbutamol was shown to increase coronary blood flow, which was subsequently shown to be the result of a direct coronary vasodilating effect of salbutamol.

In six dogs with right-sided cardiac bypass, salbutamol, given at the dose of 25 mcg/kg, improved left ventricular efficiency and increased coronary blood flow. Recent studies in minipigs, rodents, and dogs recorded the occurrence of cardiac arrhythmias and sudden death (with histologic evidence of myocardial necrosis) when beta-agonists and methylxanthines were administered concurrently. The significance of these findings when applied to humans is currently unknown.

Animal studies show that salbutamol does not pass the blood brain barrier.

Acute Toxicity

Table 3: Acute Toxicity

The rate of respiration in test animals initially increased, but subsequently became abnormally slow and deep. Death, preceded by convulsions and cyanosis, usually occurred within four hours after drug administration.

Rabbits, cats and dogs survived a single dose of 50 mg/kg salbutamol.

Intermediate (Four Months) Toxicity

Rats received salbutamol twice daily, in oral doses from 0.5 to 25 mg/kg, on an increasing scale. The only significant hematological changes were a small increase in hemoglobin and packed cell volume. BUN and SGOT values were elevated while blood glucose and plasma protein levels remained unchanged. Pituitaries had increased amount of PAS-positive material in the cleft at the higher dose levels.

Salbutamol was given to dogs twice daily, in oral doses from 0.05 to 12.5 mg/kg, on an increasing scale. The rate of increase of hemoglobin and packed cell volume was depressed, particularly at higher doses. Leukocyte count decreased after sixteen weeks of treatment at each dose level. Platelet count was increased after eight weeks at the highest dose. No significant biochemical effects were observed. The only significant histological change was the appearance of corpora amylacea in the stomach which was attributed to altered mucus secretion. Inhalation of 1000 mcg of salbutamol aerosol twice daily for three months did not produce any morphological changes in the lungs, trachea, lymph nodes, liver or heart.

Long-Term Toxicity

Fifty female, Charles River CD Albino rats received salbutamol orally at 2, 10 and 50 mg/kg/day for one hundred and four weeks; fifty female Charles River CD Sprague-Dawley-derived rats received 20 mg/kg/day salbutamol orally for fifty weeks, and fifty female Charles River Long-Evans rats received 20 mg/kg/day salbutamol orally for ninety-six weeks. These rat studies demonstrated a dose-related incidence of mesovarian leiomyomas. No similar tumors were seen in mice.

Mutagenicity

In vitro tests involving four micro-organisms revealed no mutagenic activity.

Carcinogenicity

In a two-year study in the rat, salbutamol sulfate caused a significant dose-related increase in the incidence of benign leiomyomas of the mesovarium at doses corresponding to 111, 555, and 2,800 times the maximum human inhalation dose. In another study, the effect was blocked by the co-administration of propranolol. The relevance of these findings to humans is not known. An 18-month study in mice and a lifetime study in hamsters revealed no evidence of tumorigenicity.

Teratogenicity Studies

Salbutamol has been shown to be teratogenic in mice when given in doses corresponding to 14 times the human aerosol dose; when given subcutaneously in doses corresponding to 0.2 times the maximum human (child weighing 21 kg) oral dose; and when given subcutaneously in doses corresponding to 0.4 times the maximum human oral dose.

A reproduction study in CD-1 mice given salbutamol at doses of 0.025, 0.25, and 2.5 mg/kg subcutaneously, corresponding to 1.4, 14, and 140 times the maximum human aerosol dose respectively, showed cleft palate formation in 5 of 111 (4.5%) fetuses at 0.25 mg/kg and in 10 of 108 (9.3%) fetuses at 2.5 mg/kg. No cleft palates were observed at a dose of 0.025 mg/kg salbutamol. Cleft palate occurred in 22 of 72 (30.5%) fetuses treated with 2.5 mg/kg isoprenaline (positive control).

In rats, salbutamol treatment given orally at 0.5, 2.32, 10.75 and 50 mg/kg/day throughout pregnancy resulted in no significant fetal abnormalities. However, at the highest dose level there was an increase in neonatal mortality. Reproduction studies in rats revealed no evidence of impaired fertility.

Salbutamol had no adverse effect when given orally to Stride Dutch rabbits, at doses of 0.5, 2.32 and 10.75 mg/kg/day throughout pregnancy. At a dose of 50 mg/kg/day, which represents 2800 times the maximum human inhalation dose and 78 times the maximum human oral dose cranioschisis was observed in 7 of 19 (37%) fetuses.

17 Supporting Product Monographs

1. 1. VENTOLIN Respirator Solution (solution, 5 mg/mL) and VENTOLIN NEBULES P.F. (solution, 2.5 mg / 2.5 mL and 5 mg / 2.5 mL), control 207158, product monograph, GlaxoSmithKline Inc. (2017-11-17)
2. 2. VENTOLIN Respirator Solution (solution, 5 mg/mL), control 295683, product monograph, GlaxoSmithKline Inc. (2025-08-29).